# FUTURE 3 Study Extension

> **NCT01338415** · PHASE3 · COMPLETED · sponsor: **Actelion** · enrollment: 58 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Bosentan

## Key facts

- **NCT ID:** NCT01338415
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-08
- **Primary completion:** 2014-08-13
- **Final completion:** 2020-05-29
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01338415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01338415, "FUTURE 3 Study Extension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01338415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*